Vesomni improves the quality of life in men with lower urinary tract symptoms in routine clinical practice in Europe.

AIM: To evaluate the impact of Vesomni/Urizia/Volutsa, a fixed-dose combination tablet containing 6 mg solifenacin (antimuscarinic) and 0.4 mg tamsulosin (α-blocker), on health-related quality of life (HRQoL) and treatment satisfaction in men with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) in routine clinical practice. METHODS: EUROPA was a noninterventional study of men with LUTS/BPH not responding to monotherapy who were prescribed Vesomni in routine clinical practice. Data were collected retrospectively (1 year) and prospectively (1 year). Assessments were performed at baseline, weeks 4 to 8, weeks 9 to 18 (optional), weeks 19 to 39 (optional), and Weeks 40 to 52. The primary endpoint was change from baseline in HRQoL, as assessed by the Overactive Bladder Questionnaire (OAB-q) symptom bother subscale score. Change from baseline in OAB-q total and coping, sleep, and social interaction subscale scores, treatment satisfaction-visual analog scale (TS-VAS), International Prostate Symptom Score (IPSS), and European Quality of Life 5-Dimension-5-Level (EQ-5D-5L) questionnaire were also evaluated. RESULTS: Five hundred and eighty-nine patients were enrolled. The mean changes in adjusted mean (95% confidence interval [CI]) OAB-q symptom bother subscale scores were -16.40 (-24.31, -8.49) at weeks 4 to 8 and -19.59 (-28.26, -10.92) at weeks 40 to 52; at weeks 40 to 52, changes were clinically meaningful in 84.6% of patients. Adjusted mean (95% CI) change from baseline to weeks 40 to 52 were 15.02 (7.35, 22.69), 19.37 (10.86, 27.89), 18.65 (7.44, 29.86), 9.85 (3.90, 15.81), and 16.09 (9.07, 23.11) for concern, coping, sleep, social interaction, and total, respectively. TS-VAS, IPSS, and EQ-5D-5L all improved, and treatment persistence at weeks 40 to 52 was 77.1%. Urinary retention was reported in four (0.7%) patients. CONCLUSIONS: Vesomni was well-tolerated and improved HRQoL and treatment satisfaction in patients with LUTS/BPH.

Mirabegron improves quality-of-life, treatment satisfaction, and persistence in patients with overactive bladder: a multi-center, non-interventional, real-world, 12-month study.

OBJECTIVE: Observational studies can provide evidence about patient outcomes in routine clinical practice. This prospective, non-interventional study (BELIEVE) is the largest real-world European study to date to assess quality-of-life, treatment satisfaction, resource utilization, and persistence in patients with overactive bladder (OAB) who were prescribed mirabegron as part of routine clinical practice. METHODS: The primary objective was to evaluate change from baseline in quality-of-life based on overactive bladder questionnaire (OAB-q) sub-scales. Secondary objectives included evaluation of treatment persistence, patient satisfaction, healthcare resource utilization and adverse events (AEs). Follow-up was for 12 months with visit windows at 2-4 and 10-12 months. Median change from baseline in total OAB-q and its sub-scales (Health-related quality-of-life [HRQoL] and symptom bother scale) were assessed. RESULTS: Overall, 862 patients were enrolled from eight European countries. In the Full Analysis Set (FAS), 73.7% were female, mean age was 61.2 years; 47.7% ≥65 years. At baseline, 41.3% had switched from other OAB treatments, 42.2% were treatment naïve, 10.1% were lapsed, and 6.4% were on combination treatment. Symptom bother and HRQoL total scores improved from baseline to 2-4 and 10-12 months. There was a notable improvement in dry rate, increasing from 34.9% at baseline to 43.7% at 10-12 months in the FAS, and a reduction in pad use. Persistence was high, with 53.8% of FAS patients remaining on mirabegron at 10-12 months. Overall, no unexpected safety issues were observed and AEs were consistent with the known safety profile of mirabegron. CONCLUSION: Patients receiving mirabegron in a real-world setting reported meaningful improvements in QoL and health status, with a persistence rate of 53.8% at 12 months for the FAS. No unexpected safety issues were observed, and AEs were consistent with the known safety profile of mirabegron.

Persistencia de pliegues mucosos ureterales-válvulas ureterales no obstructivas- en un niño de 11 años de edad / Persistence of ureteral mucosa folds-non obstructives ureterals valves-in a child 11 years old

No disponible

No disponible

[Penile metastasis like first sign of esophagus carcinoma]. / Metástasis peneana como primera manifestación de un carcinoma esofágico.

We present a new case of penile metastatic disease. The original tumour has been situated in the esophagus, which is a rare clinical situation. But what becomes exceptional in our clinical case is that the penile metastasis was the first disease symptom, since until this moment the original tumour has been silent. Like the majority of these cases the prognosis was gloomy and the patient died in few months after the clinical beginning of the disease.

Metástasis peneana como primera manifestación de un carcinoma esofágico / Penile metastasis like first sign of esophagus carcinoma

Presentamos un nuevo caso de enfermedad metastásica en pene. El tumor primitivo se originó en el esófago, lo que es una rareza clínica. Pero lo que hace excepcional a nuestro caso clínico es que fue la metástasis peneana el primer síntoma de la enfermedad, ya que hasta entonces el tumor primitivo permanencia silente. Como en la mayoría de casos similares el pronóstico fue pésimo y el paciente falleció a los pocos meses del inicio clínico de la enfermedad metastásica peneana (AU)

We present a new case of penile metastatic disease. The original tumour has been situated in the esophagus, which is a rare clinical situation. But what becomes exceptional in our clinical case is that the penile metastasis was the first disease symptom, since until this moment the original tumour has been silent. Like the majority of these cases the prognosis was gloomy and the patient died in few months after the clinical beginning of the disease (AU)

[Paratesticular fibrous pseudotumor]. / Pseudotumor fibroso paratesticular.

OBJECTIVE: Benign testicular proliferative processes are known by the name of pseudotumors, because currently they are not considered real neoplasias. The paratesticular fibrous pseudotumor (PFP) is a rare entity the definition and etiopathogenesis of which is under great confusion. It is a process that misleads the clinical because they simulate neoplasias. This paper aims to help a better knowledge of this non-tumoral process and to avoid diagnostic confusions. METHODS/RESULTS: We review our series of PFP (three cases), which can be considered significant due to its oddity. We analyze the clinical picture, its behavior, imaging diagnostic tests, operative findings and outcomes. CONCLUSIONS: PFP is a rare entity which may misleads the clinical because it may be diagnosed as a neoplasia and lead to aggressive treatment (orchiectomy) which in case of a proper diagnosis could be avoided. The analysis of our series of three cases, with their contribution, and a literature review may help the clinical practice of urologists by recognizing this disease.

[Thigh abscess: a very rare complication of retropubic adenomectomy]. / Abceso en muslo: rarísima complicación de una adenomectomía retropúbica.

OBJECTIVE: Usual complications of retropubic adenomectomy are well-known. Despite their low incidence, urologists face them relatively often in their daily practice due to the frequent performance of this technique, and they usually have satisfactory outcomes. We want to attract attention to the presence of a thigh abscess as an exceptional complication of adenomectomy. It is such on oddity that may pose very important diagnostic problems, with negative implications due to treatment delay. The knowledge of it may be decisive at the time of diagnosis and enable a fast decision-making process. METHODS/RESULTS: We present the case ofa great thigh abscess as a complication of adenomectomy. We performed a detailed description of its presentation and avatars occurred until diagnosis and treatment, fortunately successful. We collect the pathogenic mechanisms of dissemination and comment on bibliography. CONCLUSIONS: The presence of a thigh abscess as a late complication of adenomectomy is an exceptional entity requiring a rapid diagnosis to an enable successful treatment, because it is a severe complication.

Abceso en muslo: rarísima complicación de una adenomectomía retropúbica / Thigh abscess: a very rare complication of retropubic adenomectomy

Objetivo: Las complicaciones habituales de la adenomectomía retropúbica son perfectamente conocidas. A pesar de su baja incidencia, la amplia utilización de esta técnica hace que en el día a día el urólogo se enfrente a ellas con relativa frecuencia, y se resuelvan satisfactoriamente. Queremos llamar la atención sobre la presencia de un absceso de muslo como complicación excepcional de la adenomectomía. Es una rareza tal que nos puede plantear importantísimos problemas en su diagnóstico, con las negativas implicaciones que ello acarrea al demorar el tratamiento. Su conocimiento puede ser decisivo a la hora del diagnóstico y permitir una rápida toma de decisiones. Método/Resultado: Presentamos un caso de un gran absceso de muslo como complicación de una adenomectomía. Se efectúa una detallada descripción de su presentación y los avatares que acaecieron hasta su diagnóstico y tratamiento, afortunadamente exitoso. Recogemos los mecanismos a través de los cuales se produce la diseminación y comentamos la bibliografía. Conclusión: La presencia de un absceso en muslo como complicación tardía de una adenomectomía es una entidad excepcional que requiere un rápido diagnóstico que permita su tratamiento exitoso, pues se trata de una grave complicación (AU)

Objective: Usual complications of retropubic adenomectomy are well-known. Despite their low incidence, urologists face them relatively often in their daily practice due to the frequent performance of this technique, and they usually have satisfactory outcomes. We want to attract attention to the presence of a thigh abscess as an exceptional complication of adenomectomy. It is such an oddity that may pose very important diagnostic problems, with negative implications due to treatment delay. The knowledge of it may be decisive at the time of diagnosis and enable a fast decision-making process. Methods/Results: We present the case of a great thigh abscess as a complication of adenomectomy. We performed a detailed description of its presentation and avatars occurred until diagnosis and treatment, fortunately successful. We collect the pathogenic mechanisms of dissemination and comment on bibliography. Conclusions: The presence of a thigh abscess as a late complication of adenomectomy is an exceptional entity requiring a rapid diagnosis to an enable successful treatment, because it is a severe complication (AU)